Mark Boulding Net Worth

The estimated Net Worth of Mark Elliott Boulding is at least $6.95 Million dollars as of 30 January 2024. Mr. Boulding owns over 794 units of PTC Therapeutics Inc stock worth over $2,297,269 and over the last 11 years he sold PTCT stock worth over $2,147,738. In addition, he makes $2,509,990 as Executive Vice President und Chief Legal Officer at PTC Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Boulding PTCT stock SEC Form 4 insiders trading

Mark has made over 23 trades of the PTC Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 794 units of PTCT stock worth $21,637 on 30 January 2024.

The largest trade he's ever made was exercising 181,667 units of PTC Therapeutics Inc stock on 28 June 2019 worth over $3,402,623. On average, Mark trades about 13,146 units every 109 days since 2014. As of 30 January 2024 he still owns at least 71,189 units of PTC Therapeutics Inc stock.

You can see the complete history of Mr. Boulding stock trades at the bottom of the page.

Mark Boulding biography

Mark Elliott Boulding serves as Executive Vice President, Chief Legal Officer of the Company. He previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. He also serves as a director of one and as co-secretary of two subsidiaries of PTC. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two Washington, D.C.-based law firms. Mr. Boulding received a J.D. from the University of Michigan and a B.A. from Yale College.

What is the salary of Mark Boulding?

As the Executive Vice President und Chief Legal Officer of PTC Therapeutics Inc, the total compensation of Mark Boulding at PTC Therapeutics Inc is $2,509,990. There are 2 executives at PTC Therapeutics Inc getting paid more, with Stuart Peltz having the highest compensation of $7,759,440.

How old is Mark Boulding?

Mark Boulding is 59, he's been the Executive Vice President und Chief Legal Officer of PTC Therapeutics Inc since 2017. There are 10 older and 6 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.

What's Mark Boulding's mailing address?

Mark's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD, NJ, 07080.

Insiders trading at PTC Therapeutics Inc

Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel und Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.

What does PTC Therapeutics Inc do?

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.

Complete history of Mr. Boulding stock trades at PTC Therapeutics Inc

PTC Therapeutics Inc executives and stock owners

PTC Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stuart Peltz,
  Chief Executive Officer, Director
• Neil Almstead,
  Chief Technical Operations Officer
• Mark Boulding,
  Executive Vice President, Chief Legal Officer
• Emily Hill,
  Principal Financial Officer, Treasurer
• Dr. Stuart W. Peltz,
  Co-Founder, CEO & Exec. Director
• Christine Utter,
  Senior Vice President - Finance, Chief Accounting Officer
• Mark Elliott Boulding,
  Exec. VP & Chief Legal Officer
• Dr. Neil Almstead,
  Chief Technical Operations Officer
• Michael Schmertzler,
  Independent Chairman of the Board
• Allan Jacobson,
  Independent Director
• Emma Reeve,
  Independent Director
• David Southwell,
  Independent Director
• Dawn Svoronos,
  Independent Director
• Glenn Steele,
  Independent Director
• Jerome Zeldis,
  Independent Director
• Stephanie Okey,
  Independent Director
• Dr. Allan Steven Jacobson,
  Independent Co-Founder, Chairman of Scientific Advisory Board & Director
• Eric Pauwels,
  Chief Business Officer
• Matthew Klein,
  Chief Development Officer
• Jane Baj,
  VP of Corp. Communications
• Alex Kane,
  Investor Relations Officer
• Ellen Welch Ph.D.,
  Chief Scientific Officer
• Christine Utter,
  Sr. VP, Chief Accounting Officer & Head of People Services
• Adam Koppel,
  Director
• Cameron Geoffrey Mc Donough,
  Director
• Tuyen Ong,
  Chief Medical Officer
• Marcio Souza,
  Chief Operating Officer
• Pharma Holdings Ii, Llc Com...,
  10% owner
• Mark Rothera,
  Chief Commercial Officer
• Ronald C Jr Renaud,
  Director
• Suisse/ Credit,
  
• Claudia De Oliveira Ribeiro...,
  President
• Bioventures Cayman Ltd Hbm,
  10% owner
• Robert J. Spiegel,
  Chief Medical Officer
• Richard Aldrich,
  Director
• Ventures Inc.Vulcan Capital...,
  
• Shane William Charles Kovacs,
  EVP, CFO & Head of Corp Dev
• Axel Bolte,
  Director
• Michael L Kranda,
  Director
• Pierre Gravier,
  CHIEF FINANCIAL OFFICER
• Mary L. Smith,
  
• William F. Jr. Bell,
  
• Alethia Young,
  
• Lee Scott Golden,
  EVP & CHIEF MEDICAL OFFICER